Skip to main content

and
  1. No Access

    Article

    The mTOR inhibitor AZD8055 overcomes tamoxifen resistance in breast cancer cells by down-regulating HSPB8

    Tamoxifen, an important endocrine therapeutic agent, is widely used for the treatment of estrogen receptor positive (ER+) breast cancer. However, de novo or acquired resistance prevents patients from benefitting ...

    Jia-jie Shi, Si-meng Chen, Chen-liang Guo, Yi-xue Li in Acta Pharmacologica Sinica (2018)